| |
 |
 |
|
| |
Address:
377 Saw Creek Estates,
Bushkill, PA18324, USA
Tel: +1 570-588-3854
Fax: +1 702-995-3905
+1 570-588-3213
Email:
info@pharmachinaonline.com |
| |
|
|
 |
| |
| |
|
 |
| |
| Title: |
Sinobiomed phase IIb trials of biological anti-bleeding agent ongoing (2008) |
| Type： |
Pharmaceutical Chemical(NCE) |
| Status： |
Discovery |
Targeted
Indication(s): |
biological anti-bleeding agent |
| Developer(s): |
Sinobiomed Inc. |
Description
/Summary： |
Sinobiomed Inc. is currently conducting Phase IIb clinical trials of its anti-bleeding agent, recombinant Batroxobin (rBAT), with multiple test groups totalling 328 patients in seven hospitals in China. Results are expected before year's end. Should the product proceed to Phase III clinical trials, it is expected that international governments and organizations would show significant interest. Sinobiomed has already received indications of interest from global pharmaceutical companies for joint development, marketing and production.
|
Additional
Info/Comments: |
Native batroxobin, extracted from pit viper venom, is the world's most prescribed biological anti-bleeding agent. Since rBAT is produced through genetic engineering, it reduces the risk of biological contamination and neurotoxicity that have been associated with native batroxobin. |
|
|
